絞り込み

16641

広告

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.

著者 Tanaka Y , Oba K , Koike T , Miyasaka N , Mimori T , Takeuchi T , Hirata S , Tanaka E , Yasuoka H , Kaneko Y , Murakami K , Koga T , Nakano K , Amano K , Ushio K , Atsumi T , Inoo M , Hatta K , Mizuki S , Nagaoka S , Tsunoda S , Dobashi H , Horie N , Sato
Ann Rheum Dis.2019 Oct 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

The aim of this study is to determine whether the 'programmed' infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontinuation of IFX for 1 year.
PMID: 31630117 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード